The American College of Radiology Imaging Network (ACRIN) is planning a new clinical trial, designed to prospectively validate if FDG can serve as predictive marker of tumor response and patient outcome in non-small cell lung cancer (NSCLC) patients.
The trial aims to determine whether PET can effectively and consistently measure quantitative changes in FDG uptake during chemotherapy, resulting in an early indication about therapy effectiveness in advanced NSCLC, according to ACRIN.
ACRIN 6678, to be led by Dr. Wolfgang Weber of UCLA Medical Center, will be one of the first trials implemented by the Oncology Biomarker Qualification Initiative (OBQI). OBQI is a collaboration of the U.S. National Cancer Institute (NCI), Federal Drug Administration (FDA), and the Centers for Medicare & Medicaid Services (CMS) designed to qualify biomarkers for use in clinical trials.
More than 10 sites in the U.S. are expected to enroll 228 patients in two years, ACRIN said.
By AuntMinnie.com staff writers
April 3, 2007
Related Reading
ACR launches CRO business, March 15, 2007
ACR releases new MR safety guidelines, March 1, 2007
ACR launches international volunteer services portal, November 20, 2006
NEMA, ACR to lead ethics talk at RSNA, November 2, 2006
ACR remains optimistic as clock winds down on DRA implementation, October 24, 2006
Copyright © 2007 AuntMinnie.com
